Recordati posted preliminary 2025 results that extend its run as one of Europe’s most profitable mid-cap pharmas: net revenue rose 11.8% to €2.62 billion, EBITDA increased 14.5% to €991 million with a 37.8% margin, and adjusted net income grew 14.5% to €651 million. The growth engine was rare diseases, up 29.7% to €1.08 billion, fueled by accelerating U.S. uptake of Isturisa following its expanded FDA label to the broader Cushing’s syndrome population and a first full-year contribution from Enjaymo within hema-oncology. For 2026, Recordati guides to €2.73–€2.80 billion in revenue despite a projected FX headwind of about 3.5%, and €995 million–€1.03 billion in EBITDA, implying a still-elevated margin near 36.5%.
The numbers underscore a strategic pivot that has Recordati leaning harder into orphan endocrinology and hema-oncology while staying modality-agnostic through BD. It is integrating acquired and in-licensed assets (Enjaymo, Eligard in the UK, Inrebic in Japan) and expanding labels (Isturisa) even as it prunes where access proves intractable, exemplified by the voluntary liquidation of its rare disease unit in China after Isturisa missed NRDL inclusion. The question now is whether Recordati can preserve sector-leading margins while underwriting next-wave innovation and launch costs, including a potential move into genetic medicines through a collaboration on Moderna’s mRNA-3927 for propionic acidemia.
For patients and HCPs, the Isturisa expansion reframes Cushing’s syndrome management beyond the pituitary subset, with the company reporting roughly 1,400 net active U.S. patients by year-end and plans for a Phase IV study in mild hypercortisolemia with uncontrolled hypertension. Payers will recalibrate coverage in a broader, heterogeneous population where long-term monitoring and adrenal safety are central to value perception. Competitively, the field remains dynamic with therapies from Corcept and Xeris in play, sharpening the need for real-world outcomes to differentiate on efficacy, tolerability, and adherence. In hema-oncology, continued growth of Sylvant and Qarziba supports scale, but U.S. monetization of Qarziba is deferred until BEACON‑2 data expected in 2028, extending reliance on ex-U.S. markets and heightening the importance of sustained access work.
Commercially, the 2025 deal to commercialize Vazkepa across 59 countries is a calculated bet that high-risk cardiovascular prevention can gain traction in cost-conscious European systems, where physician education, primary care integration, and country-by-country reimbursement will determine whether the asset delivers the targeted EBITDA positivity in 2026 and €40 million in 2027 revenue. In Japan, mid‑2026 launch of Inrebic sets a focused growth vector in myelofibrosis. The Moderna partnership signals a broader industry shift: mid-cap rare disease specialists becoming go-to commercial engines for genetic medicines as platform biotechs prioritize development. If mRNA-3927 reads out by end‑2026 and ultimately reaches market, Recordati would be positioned to translate an emerging modality into real-world uptake across its 150-country footprint, testing payer willingness for first-in-class disease-modifying therapies in ultra-rare settings.
Balance sheet flexibility remains intact with net leverage just below 2.1x EBITDA and €559 million in free cash flow despite U.S. inventory build and higher tax and interest outflows, leaving room for bolt-on deals that have defined European orphan consolidation. The near-term watch list is clear: can Recordati defend a mid‑30s EBITDA margin while funding U.S. growth in rare endocrinology, converting Vazkepa into a European primary care revenue stream, and preparing for possible mRNA and hema-onc launches? As FX headwinds persist and payer scrutiny intensifies, the company’s ability to turn label wins and BD into durable, reimbursed patient journeys will determine whether today’s rare disease momentum hardens into a sustainable multi-modality growth arc.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
